Abstract:Background/Objectives: Breast cancer is the second most common malignancy worldwide and poses a significant threat to women's health. However, the prognostic biomarkers and therapeutic targets of breast cancer are unclear. A prognostic model can help in identifying biomarkers and targets for breast cancer. In this study, a novel prognostic model was developed to optimize treatment, improve clinical prognosis, and screen potential phosphoglycerate kinase 1 (PGK1) inhibitors for breast cancer treatment. Methods: Using data from the Gene Expression Omnibus (GEO) database, differentially expressed genes (DEGs) were identified in normal individuals and breast cancer patients. The biological functions of the DEGs were examined using bioinformatics analysis. A novel prognostic model was then constructed using the DEGs through LASSO and multivariate Cox regression analyses. The relationship between the prognostic model, survival, and immunity was also evaluated. In addition, virtual screening was conducted based on the risk genes to identify novel small molecule inhibitors of PGK1 from Chemdiv and Targetmol libraries. The effects of the potential inhibitors were confirmed through cell experiments. Results: A total of 230 up- and 325 down-regulated DEGs were identified in HER2, LumA, LumB, and TN breast cancer subtypes. A new prognostic model was constructed using ten risk genes. The analysis from The Cancer Genome Atlas (TCGA) indicated that the prognosis was poorer in the high-risk group compared to the low-risk group. The accuracy of the model was confirmed using the ROC curve. Furthermore, functional enrichment analyses indicated that the DEGs between low- and high-risk groups were linked to the immune response. The risk score was also correlated with tumor immune infiltrates. Moreover, four compounds with the highest score and the lowest affinity energy were identified. Notably, D231-0058 showed better inhibitory activity against breast cancer cells. Conclusions: Ten genes (ACSS2, C2CD2, CXCL9, KRT15, MRPL13, NR3C2, PGK1, PIGR, RBP4, and SORBS1) were identified as prognostic signatures for breast cancer. Additionally, results showed that D231-0058 (2-((((4-(2-methyl-1H-indol-3-yl)-1,3-thiazol-2-yl)carbamoyl)methyl)sulfanyl)acetic acid) may be a novel candidate for treating breast cancer.

Screening of the Receptor of Vascular-Endothelial-cell-specific Binding Peptide GEBP11 in Gastric Cancer by Immunoprecipitation

Screening and Identification of Vascular-Endothelial-cell-specific Binding Peptide in Gastric Cancer

The Role of Vascular Endothelial Growth Factor Receptor (KDR) in Invasion and Metastasis of Gastric Cancer

188Re-Labeled GX1 Dimer As a Novel Dual-Functional Probe Targeting TGM2 for Imaging and Antiangiogenic Therapy of Gastric Cancer

Screening and identification of CD44v9 specific peptide ligand for gastric cancer detection

Screening and identification of a CD44v6 specific peptide using improved phage display for gastric cancer targeting

Establishment of a Sandwich ELISA Method for Detection of Vascular Endothelial Growth Factor in Serum Samples of Hepatocellular Carcinoma Patients

Selection of a Specific Binding Peptide Targeting to Blood Vessel of Human Gastric Cancer in Vivo and Modeling of Its Three Dimensional Structure

Identification Of Vegfr2-Binding Peptides Using High Throughput Bacterial Display Methods And Functional Assessment

Screening and Characterization of Inhibiting Peptides Binding to the Tumor Vascular Growth Factor Receptor

The further characterization of the peptide specifically binding to gastric cancer

Identification and Validation of Kallikrein-Ralated Peptidase 11 As A Novel Prognostic Marker of Gastric Cancer Based on Immunohistochemistry

Preliminary Study of Molecular Imaging of Human Hepatoceilular Carcinoma Xenoggaft with Gd-based MR Probe Containiug Arginine-Glycine-aspartic Acid Chelate

Characterization of a specific phage-displayed Peptide binding to vasculature of human gastric cancer.

Discovery Novel VEGFA Inhibitors Through Structure-Based Virtual Screening and verify the ability to inhibit the proliferation, invasion and migration of gastric cancer

Preliminary study of molecular imaging of human hepatocellular carcinoma xenograft with Gd-based MR probe containing arginine-glycine-aspartic acid chelate

A CD44 specific peptide developed by phage display for targeting gastric cancer

Expression of vascular endothelial growth factor and its receptors KDR and Flt-1 in gastric cancer cells.

KIT-SNAP-tag/cell membrane chromatography model coupled with liquid chromatography-mass spectrometry for anti-GIST compound screening from Evodia rutaecarpa

Screening of a specific peptide binding to esophageal squamous carcinoma cells from phage displayed peptide library.

Identification of a Potential PGK1 Inhibitor with the Suppression of Breast Cancer Cells Using Virtual Screening and Molecular Docking